Abstract: Described are four, novel supercritical fluid extracts of Nigella sativa seeds containing about 0.01 to about 40% (w/w) thymoquinone that can be produced using commercial-scale quantities of N. sativa seeds. These formulations provide antioxidant, thermogenic, anti-inflammatory and other biological activities qualitatively and quantitatively distinct from thymoquinone alone and are useful as dietary supplements or therapeutics for inflammation-related disorders.

Abstract: Described are four, novel supercritical fluid extracts of Nigella sativa seeds containing about 0.01 to about 40% (w/w) thymoquinone that can be produced using commercial-scale quantities of N. sativa seeds. These formulations provide antioxidant, thermogenic, anti-inflammatory and other biological activities qualitatively and quantitatively distinct from thymoquinone alone and are useful as dietary supplements or therapeutics for inflammation-related disorders.

Abstract: Described are four, novel supercritical fluid extracts of Nigella sativa seeds containing about 0.01 to about 40% (w/w) thymoquinone that can be produced using commercial-scale quantities of N. sativa seeds. These formulations provide antioxidant, thermogenic, anti-inflammatory and other biological activities qualitatively and quantitatively distinct from thymoquinone alone and are useful as dietary supplements or therapeutics for inflammation-related disorders.

Abstract: Disclosed are botanically based compositions and methods useful for the treatment of metabolic syndrome and diabetes type 2. Compositions, kits, and methods are additionally disclosed for means to augment the activity of identified glucose and insulin regulating drugs.

Abstract: Botanical compounds to modulate kinase activity are disclosed. The compounds and methods disclosed also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively. The compositions contain at least one fraction isolated or derived from hops or Acacia.

Abstract: Disclosed are botanically based compositions and methods useful for the treatment of metabolic syndrome and diabetes type 2. Compositions, kits, and methods are additionally disclosed for means to augment the activity of identified glucose and insulin regulating drugs.

Abstract: Methods for treating or preventing metabolic dysregulation of adipocytes resulting from HIV-1 infection or chronic inflammation are disclosed. The compositions contain a conjugated fatty acid, a thiol-containing compound and a bioavailable form of trivalent chromium.

Abstract: A novel dietary supplement or therapeutic composition is provided that serves to treat lower urinary tract disorders or to support normal urinary tract function in animals. The supplement comprises a thymoquinone formulation and at least one member of the group consisting of cranberry fruit, cranberry extract, cranberry juice and a pharmaceutical grade methionine.

Abstract: Compositions for treating or preventing fat maldistribution or hyperlipidemia resulting from anti-retroviral treatment of HIV-1 infection are disclosed. The compositions contain a conjugated fatty acid or alcohol and at least one member selected from the group consisting of a thiol-containing compound and a bioavailable form of trivalent chromium. Methods of treating a subject suffering from HIV-associated fat maldistribution or hyperlipidemia by administering a composition that includes a conjugated fatty acid or conjugated fatty alcohol and at least one member selected from the group consisting of a thiol-containing compound and a bioavailable form of trivalent chromium are similarly provided.

Abstract: Described are four, novel supercritical fluid extracts of Nigella sativa seeds containing about 0.01 to about 40% (w/w) thymoquinone that can be produced using commercial-scale quantities of N. sativa seeds. These formulations provide antioxidant, thermogenic, anti-inflammatory and other biological activities qualitatively and quantitatively distinct from thymoquinone alone and are useful as dietary supplements or therapeutics for inflammation-related disorders.

Abstract: Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on xanthohumol or isoxantohumol, or tetrahydro-isoalpha acids commonly found in hops.

Abstract: Disclosed are methods, compounds, and compositions comprising botanically based drugs, medical foods, and dietary supplements for the prevention and treatment of metabolic disorders, in particular obesity, weight gain, insulin resistance syndromes, diabetes, fasting hyperlipidemia and osteoarthritis. More specifically, the invention relates to pharmaceutical therapeutic methods and compositions utilizing phytochemicals, natural plant extracts and combinations to modify adipocyte physiology to enhance thermogenesis and modify cytokine secretion.

Abstract: Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on xanthohumol or isoxantohumol, or tetrahydro-isoalpha acids commonly found in hops.

Abstract: Compounds and methods for multi-targeted protein kinase modulation for angiogenesis, cancer treatment or the inflammatory pathways associated with those conditions are disclosed. The compounds and methods disclosed are based on substituted 1,3-cyclopentadione compounds.

Abstract: A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a curcuminoid species and an effective amount of a second component selected from the group consisting of an alpha-acid species or a beta-acid species or derivatives thereof. The composition provides synergistic anti-inflammatory effects in response to physical or chemical injury or abnormal immune stimulation due to a biological agent or unknown etiology.

Abstract: A novel dietary supplement or therapeutic composition is provided that serves to treat lower urinary tract disorders or to support normal urinary tract function in animals. The supplement comprises a thymoquinone formulation and at least one member of the group consisting of cranberry fruit, cranberry extract, cranberry juice and a pharmaceutical grade methionine.

Abstract: A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a curcuminoid species and an effective amount of a second component selected from the group consisting of an alpha-acid species or a beta-acid species or derivatives thereof. The composition provides synergistic anti-inflammatory effects in response to physical or chemical injury or abnormal immune stimulation due to a biological agent or unknown etiology.

Abstract: A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a curcuminoid species and an effective amount of a second component selected from the group consisting of an alpha-acid species or a beta-acid species or derivatives thereof. The composition provides synergistic anti-inflammatory effects in response to physical or chemical injury or abnormal immune stimulation due to a biological agent or unknown etiology.

Abstract: According to the present invention, the biological or pharmacological activity of a test material like a plant or herbal material, an extract of a plant or herbal material, a natural or synthetic compound or some combination thereof, can be quantified by observing the pattern of structural changes induced in a eukaryotic cell's proteins. These structural changes may be evidenced by protein phosphorylation, by protein-protein interactions and the like. The amount and nature of protein phosphorylation is qualitatively and quantitatively related to the in vitro concentration of biologically/pharmacologically active components to which the mammalian cells are exposed. Additionally, formation or loss of protein-protein complexes may be determined in whole cell homogenates through the use of nondenaturing electrophoresis and staining for proteins or protein phosphorylation.

Abstract: According to the present invention, the biological or pharmacological activity of a test material like a plant or herbal material, an extract of a plant or herbal material, a natural or synthetic compound or some combination thereof, can be quantified by observing the pattern of structural changes induced in a eukaryotic cell's proteins. These structural changes may be evidenced by protein phosphorylation, by protein-protein interactions and the like. The amount and nature of protein phosphorylation is qualitatively and quantitatively related to the in vitro concentration of biologically/pharmacologically active components to which the mammalian cells are exposed. Additionally, formation or loss of protein-protein complexes may be determined in whole cell homogenates through the use of non-denaturing electrophoresis and staining for proteins or protein phosphorylation.